

Rule 4.7B

## Appendix 4C

### Quarterly report for entities admitted on the basis of commitments

Name of entity

<b>Starpharma Pooled Development Limited</b>
--

ABN

<b>20 078 532 180</b>
-----------------------

Quarter ended ("current quarter")

<b>31 December 2002</b>
-------------------------

#### Consolidated statement of cash flows

##### Cash flows related to operating activities

	Current Quarter \$A'000	Year to Date \$A'000
1.1 Receipts from customers	464	464
1.2 Payments for		
(a) staff costs	(1,073)	(2,053)
(b) advertising and marketing	(16)	(39)
(c) research and development	(1,918)	(3,797)
(d) leased assets	(2)	(4)
(e) other working capital	-	-
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	159	420
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other - GST recovered	-	(20)
<b>Net operating cash flows</b>	<b>(2,386)</b>	<b>(5,029)</b>

##### Cash flows related to investing activities

1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(212)	(1,337)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other	-	-
<b>Net investing cash flows</b>	<b>(212)</b>	<b>(1,337)</b>
1.14 <b>Total operating and investing cash flows</b>	<b>(2,598)</b>	<b>(6,366)</b>

**Cash flows related to financing activities**

1.15	Proceeds from issues of shares (including oversubscriptions)	-	193
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other:	-	-
	<b>Net financing cash flows</b>	-	193
	<b>Net increase (decrease) in cash held</b>	(2,598)	(6,173)
1.21	Cash at beginning of quarter/year to date	13,867	17,434
1.22	Exchange rate adjustments	(1)	7
1.23	<b>Cash at end of quarter</b>	11,268	11,268

**Payments to directors of the entity and associates of the directors****Payments to related entities of the entity and associates of the related entities**

	Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2
1.25	Aggregate amount of loans to the parties included in item 1.11
1.26	Explanation necessary for an understanding of the transactions

Item 1.24 consists of the following:

(a) Remuneration paid to the Chief Executive Officer.

(b) Directors' Fees.

(c) Payments to Biomolecular Research Institute Ltd:

A Director, Prof. P M Colman, is a Director of the Biomolecular Research Institute Ltd which provided some administrative services to the entity. These dealings with the entity are in the ordinary course of business and on normal terms of business.

The aggregate amount of these transactions for this supplier included in item 1.24 is \$4,523.

**Non-cash financing and investing activities**

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

Nil

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Nil

**Financing facilities available**

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

- 3.1 Loan facilities
- 3.2 Credit standby arrangements - Credit card facility (total facility \$120,000)

Amount available \$A'000	Amount used \$A'000
-	-
120	4

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,075	1,785
4.2 Deposits at call	10,193	12,082
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)	<b>11,268</b>	<b>13,867</b>

**Acquisitions and disposals of business entities**

- 5.1 Name of entity
- 5.2 Place of incorporation or registration
- 5.3 Consideration for acquisition or disposal
- 5.4 Total net assets
- 5.5 Nature of business

Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
-	-
-	-
-	-
-	-
-	-

**Compliance statement**

- This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Law (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- This statement does give a true and fair view of the matters disclosed.



B P Rogers  
Company Secretary

Date: 31 January 2003



31 January, 2003

## **QUARTERLY CASH FLOW REPORT FOR PERIOD ENDED 31 DECEMBER 2002**

Attached is Appendix 4C – Quarterly report for entities admitted on the basis of commitments – for the period ended 31 December 2002.

The cash balance for the Starpharma group as at the end of December 2002 was \$11.27m. Net cash outflow (including capital expenditure) for the quarter was \$2.60m, compared with \$3.57m for the previous quarter. Expenditure remains within budget forecasts, and based on current projected activities the Company has cash reserves to continue for at least 18 months.

These forecasts do not include estimates of new grant and licensing income, which continues to be a management focus.

A handwritten signature in black ink, appearing to read "John W Raff".

John W Raff  
Chief Executive Officer

---

### **CONTACTS:**

**Dr John Raff**  
Chief Executive Officer

**Mr Ben Rogers**  
Company Secretary